Head-To-Head Analysis: Novartis (NVS) and Adamis Pharmaceuticals (ADMP)
Novartis (NYSE: NVS) and Adamis Pharmaceuticals (NASDAQ:ADMP) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Risk & Volatility
Novartis has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
11.1% of Novartis shares are owned by institutional investors. Comparatively, 16.5% of Adamis Pharmaceuticals shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 12.2% of Adamis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Novartis and Adamis Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Novartis||$49.11 billion||3.96||$7.70 billion||$3.25||25.85|
|Adamis Pharmaceuticals||$6.47 million||18.71||-$19.43 million||($0.70)||-5.18|
Novartis has higher revenue and earnings than Adamis Pharmaceuticals. Adamis Pharmaceuticals is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.
Novartis pays an annual dividend of $2.30 per share and has a dividend yield of 2.7%. Adamis Pharmaceuticals does not pay a dividend. Novartis pays out 70.8% of its earnings in the form of a dividend.
This table compares Novartis and Adamis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for Novartis and Adamis Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Novartis currently has a consensus price target of $84.41, suggesting a potential upside of 0.47%. Adamis Pharmaceuticals has a consensus price target of $10.33, suggesting a potential upside of 185.06%. Given Adamis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Adamis Pharmaceuticals is more favorable than Novartis.
Novartis beats Adamis Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company’s range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.